How does this panel compare to simple BRCA testing, and what is the advantage?

The advantage is a faster, more complete picture, ensuring you don't miss medically actionable variants that guide personalized risk management and therapeutic decisions.

What is Creative Biolabs' strategy for handling a variant of uncertain significance (VUS)?

Our service includes specialized bioinformatics filtering and expert interpretation to minimize VUS reporting. Crucially, we offer a reclassification service, continuously monitoring new scientific literature to upgrade or downgrade VUS status.

What type of sample is required, and how sensitive is the test for detecting different mutation types?

We primarily require high-quality genomic DNA extracted from blood or saliva. Our NGS platform achieves high depth and uniformity, ensuring superior sensitivity for detecting not only single-nucleotide variants but also crucial large-scale genomic rearrangements.

Cancer Predisposition & Susceptibility Gene Panel Analysis Service

The most significant problem in hereditary cancer assessment is the reliance on incomplete or focused data, resulting in missed risk stratification and delayed therapeutic intervention. Creative Biolabs' comprehensive multi-gene panel testing (MGPT) approach directly solves this by moving beyond single-gene analysis to deliver an integrated, actionable germline profile. This method minimizes the risk of overlooking pathogenic variants in moderate-penetrance genes (e.g., ATM, CHEK2), which robust medical data shows can account for an additional 4% to 8% of carriers who would have been missed by traditional, focused testing.

Introduction of Cancer Predisposition Panel Analysis

Cancer predisposition panel analysis is a next-generation sequencing approach used to simultaneously assay multiple germline genes linked to increased lifetime cancer risk. Hereditary cancer syndromes account for 5-10% of all cancers, and the inability of family history alone to identify all carriers mandates a more comprehensive approach. Published data show that MGPT is a highly cost-effective strategy, dramatically increasing diagnostic yield and justifying its application in both high-risk and population screening settings, thereby establishing a new standard for proactive risk prevention.

Strategic Medical and Research Solutions

Our core solutions deliver essential medical utility for individual management and vital data for therapeutic research:

Guiding Precision Treatment Stratification

We provide germline results for BRCA1/2 and a full suite of homologous recombination repair (HRR) pathway genes, which are critical therapeutic targets. Identifying these variants qualifies individuals with certain advanced solid tumors for targeted therapies, such as PARP inhibitors, or determines eligibility for specific immunotherapies based on DNA mismatch repair status.

Optimizing Prevention and Surveillance

For asymptomatic or high-risk individuals, a positive finding enables the immediate design of personalized, enhanced surveillance protocols. This includes initiating screening at an earlier age, utilizing enhanced imaging modalities, or offering risk-reducing procedures, which are foundational to proactive family health management.

Enabling Accurate Research Cohorting

We supply reliable, systematic germline status to researchers, overcoming the critical flaw of relying solely on tumor-only sequencing to identify inherited risk. This systematic approach is mandated for ensuring the detection of critical predisposing variants, such as those in TP53 and NF1, which are often missed otherwise.

To discuss your specific project needs and see how our data can transform your medical or research strategy, contact our expert team today.

Workflow: From Sample to Actionable Insight

We have optimized our end-to-end workflow to ensure speed, accuracy, and maximum utility, providing clients with a clear and reliable process.

Publication

This study analyzed individuals using a 36-gene panel for hereditary cancer. Pathogenic variants were found in 22.1%, with 43.6% in BRCA1/2 and the rest in other risk genes. Testing only BRCA1/2 would have missed over half of positive cases; multi-gene analysis significantly improved detection. Notably, 9.5% of carriers had two pathogenic variants. These results highlight the importance of comprehensive multi-gene testing for accurate risk assessment and personalized clinical management.

Fig.1 Positive panel testing results in individuals: Genes and findings categorized by associated cancer risk level. (OA Literature)

Fig.1 Pathogenic variants in a multi-gene panel: Results from individuals stratified by gene and cancer risk category. ¹

Why Choose Us?

Creative Biolabs is a trusted leader in germline genetic analysis, offering unparalleled depth, quality assurance, and scientific excellence for over 20 years. Our commitment begins with a robust next-generation sequencing (NGS) platform capable of high-throughput sequencing with exceptional depth, ensuring the detection of point mutations and crucial large-scale genomic rearrangements. Our meticulously curated panel design covers the full spectrum of high- and moderate-penetrance genes, consistently delivering a higher rate of actionable findings. We guarantee the highest quality and regulatory compliance, supported by a robust bioinformatics pipeline and expert curation that reduces diagnostic uncertainty and provides clear, reliable reporting suitable for regulatory submission.

FAQs

Customer Review

Related Services

To further maximize the utility of your germline data and research objectives, Creative Biolabs offers several complementary services that can be paired with our panel analysis:

NGS-based Tumor Profiling

Creative Biolabs utilizes its NGS platform to provide an accurate, comprehensive tumor profiling service. This enables rapid identification of numerous mutations using low DNA input (10 ng) for biomarker discovery and development.

Learn More →

NGS based Genome Sequencing Service

Creative Biolabs leverages NGS for high-throughput, cost-effective sequencing in cancer genomics, infectious disease, and biomarker discovery, delivering accurate, actionable insights.

Learn More →

How to Contact Creative Biolabs

Creative Biolabs' service delivers the most comprehensive, cost-effective, and medically actionable data available today. By choosing our certified NGS platform and expert bioinformatics, you move beyond guesswork to embrace genomic precision, driving both early disease prevention and advanced therapeutic targeting.